Fluticasone propionate aerosol is more effective for prevention than treatment of recurrent airway obstruction.
Authors: Robinson N E, Berney C, Behan A, Derksen F J
Journal: Journal of veterinary internal medicine
Summary
# Editorial Summary: Fluticasone Propionate for Recurrent Airway Obstruction Recurrent airway obstruction (RAO) management relies heavily on corticosteroids, yet evidence comparing inhaled fluticasone propionate (FP) to systemic dexamethasone (DEX) has been limited to long-term treatment protocols. Robinson and colleagues conducted crossover trials in nine RAO-affected horses to evaluate FP's efficacy in two distinct scenarios: acute treatment of exacerbations and prevention of flare-ups. When treating active RAO episodes, DEX outperformed FP, with 6 mg doses of inhaled FP requiring 72 hours to significantly reduce pleural pressure changes compared to DEX's 48-hour response, whilst the lower 3 mg FP dose showed no meaningful effect—a finding supported by greater cortisol suppression with DEX. Conversely, the prevention trial revealed a markedly different picture: both high-dose FP (6 mg twice daily) and DEX equally prevented the airway pressure increases seen in untreated controls, with comparable cortisol effects and no adverse outcomes including laminitis risk. For practitioners, this suggests inhaled FP's clinical value lies primarily in prophylactic protocols for RAO-prone horses rather than acute crisis management, where systemic dexamethasone remains superior; further investigation into lower maintenance FP doses could optimise prevention strategies whilst minimising systemic steroid exposure.
Read the full abstract on PubMed
Practical Takeaways
- •FP is better suited for prevention of RAO exacerbations than for treating acute episodes; consider it as maintenance therapy rather than acute rescue treatment
- •For acute RAO flare-ups, dexamethasone remains superior and should be first choice; reserve FP 6 mg for preventive management in horses with recurrent exacerbations
- •Lower FP doses below 6 mg q12h may be effective for prevention and warrant further evaluation to reduce cost and systemic effects
Key Findings
- •Fluticasone propionate 6 mg q12h decreased maximal pleural pressure by 72 hours in acute RAO exacerbations, while 3 mg dose had no significant effect
- •Both FP 6 mg q12h and dexamethasone 0.1 mg/kg q24h were equally effective at preventing acute RAO exacerbations
- •Dexamethasone was more effective than FP for acute treatment of RAO exacerbations, decreasing cortisol more substantially
- •Neither FP nor DEX affected bronchoalveolar lavage fluid cytology or caused evidence of laminitis during treatment